The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

被引:0
作者
Min Yuan
Li-Li Huang
Jian-Hua Chen
Jie Wu
Qing Xu
机构
[1] Tongji University School of Medicine,Department of Oncology, Dermatology Hospital
[2] Tongji University School of Medicine,Department of Oncology, Shanghai Tenth People’s Hospital
[3] University of Oklahoma Health Sciences Center,Peggy and Charles Stephenson Cancer Center
[4] University of Oklahoma Health Sciences Center,Department of Pathology
来源
Signal Transduction and Targeted Therapy | / 4卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Lung cancer is one of the most common cancer in the world. In 2018, there were over 2 million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer. Targeted therapy has emerged as an important mean of the disease management for patients with non-small-cell lung cancer (NSCLC). Herein, we review and analyze recent literature, discuss the targeting pathways and ongoing clinical trials in lung cancer. Chemotherapy is no longer the best available treatment for all patients. Therapeutic decisions should be guided by an understanding of the molecular features of patient’s tumor tissues. The future gains will likely emerge from finding optimal ways of combining targeted therapy, immunotherapy, and chemotherapy.
引用
收藏
相关论文
共 50 条
[21]   Time for molecularly targeted maintenance therapy for non-small-cell lung cancer? [J].
Stinchcombe, Thomas E. ;
Ramalingam, Suresh S. .
LANCET ONCOLOGY, 2010, 11 (06) :500-501
[22]   Emerging therapies in non-small-cell lung cancer [J].
Khuri, FR ;
Herbst, RS ;
Fossella, FV .
ANNALS OF ONCOLOGY, 2001, 12 (06) :739-744
[23]   Emerging drugs for non-small-cell lung cancer [J].
Felip, Enriqueta ;
Santarpia, Mariacarmela ;
Rosell, Rafael .
EXPERT OPINION ON EMERGING DRUGS, 2007, 12 (03) :449-460
[24]   Correction: Targeted therapy in non-small-cell lung cancer—is it becoming a reality? [J].
F. Janku ;
D. J. Stewart ;
R. Kurzrock .
Nature Reviews Clinical Oncology, 2011, 8 :384-384
[25]   Targeted therapy in non-small-cell lung cancer-is it becoming a reality? [J].
Janku, Filip ;
Stewart, David J. ;
Kurzrock, Razelle .
NATURE REVIEWS CLINICAL ONCOLOGY, 2010, 7 (07) :401-414
[26]   Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer [J].
Giovannetti, Elisa ;
Erdem, Lale ;
Olcay, Efnan ;
Leon, Leticia G. ;
Peters, Godefridus J. .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2011, 16 :116-130
[27]   Is there a role for maintenance therapy in non-small-cell lung cancer? An emerging issue [J].
Petrelli, Fausto ;
Ghilardi, Mara ;
Cremonesi, Marco ;
Cabiddu, Mary ;
Barni, Sandro .
EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (10) :1455-1465
[28]   Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer [J].
Pabani, A. ;
Butts, C. A. .
CURRENT ONCOLOGY, 2018, 25 :S94-S102
[29]   Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC) [J].
Tiseo, M. ;
Bartolotti, M. ;
Gelsomino, F. ;
Bordi, P. .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2010, 4 :81-98
[30]   Integrating new targeted agents into the treatment of non-small-cell lung cancer [J].
Thatcher, Nick .
LUNG CANCER, 2006, 54 :S25-S31